Biotechnology · Nasdaq

MRNAModerna, Inc.

Last close
$223.37 -3.5%
52-week range
$22.28 to $280.80
Market cap
$90.4B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$1.94B
-40% vs FY24
Net income
-$2.82B
+21% vs FY24
Free cash flow
-$2.06B
+49% vs FY24
Net cash
$5.21B
Cash $5.80B, debt $590M

Stock price

+1,101% since Dec 2018

Valuation vs its own history since 2018

Above its median since 2018 on 1 multiple

Where each multiple sits today inside its own range since 2018, measured at every quarter end. The thin tick is the median.

P/E, trailing
n/a
n/a: No earnings
Median 11.1x, range 4.3x to 105x
Price / sales
35.8x
2.3x231x
75th percentile, above its median of 8.5x
EV / EBITDA
n/a
n/a: Not meaningful (negative or missing)
Median 8.8x, range 3.0x to 72.3x
Price / free cash flow
n/a
n/a: Not meaningful (negative or missing)
Median 11.2x, range 5.6x to 102x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
n/aNo earnings
Earnings yield
-3.2%
Price / sales
35.8x
Price / book
13.2x
Price / operating cash flow
n/a
EV / EBITDA
n/a
EV / sales
33.7x
Free cash flow yield
-2.2%

n/a: Not reported

Profitability

Gross margin
28.0%
Operating margin
-116%
Net margin
-110%
Return on equity
-40.8%
Return on capital
-33.9%

Growth per year

Revenue, 3 years
-53.4%
Revenue, 5 years
+19.3%
Revenue, 9 years
+37.8%
EPS, 3 years
n/aNot meaningful (a loss in the window)

Balance sheet

Cash and investments
$5.17B
Total debt
n/a
Net cash
$5.17B
Debt / equity
n/a
Current ratio
3.62x

n/a: No debt reported

Shares and dividend

Shares outstanding
405M
Share count, 5 years
+2.1%
Beta, 1 year
2.37
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 39 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $1.31B
RevenueNet income
Gross profitLatest quarter $995M
EBITDALatest quarter $191M
Margins76 / 10 / 12%
GrossOperatingNet
Earnings per shareLatest quarter $0.38
Cash flowLatest quarter -$1.56B
OperatingCapexFree
Cash vs debtLatest quarter $5.17B
Cash and investmentsTotal debt
P/E historyNow n/a
P/E, median 11.1x dashed
P/S historyNow 35.8x
P/S, median 8.5x dashed

Where the revenue comes from

Collaboration Arrangement Including Arrangements With Affiliate went from 2% to 1% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

Product SalesSt and Ready Manufacturing RevenueGrantCollaboration Arrangement Including Arrangements With AffiliateLicense and RoyaltyRSV
FY22
$19.3B
FY23
$6.85B
FY24
96%
$3.24B
FY25
94%
$1.94B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Product Sales$1.82B93.5%-42%
St and Ready Manufacturing Revenue$80.0M4.1%n/a
Grant$22.0M1.1%-41%
Collaboration Arrangement Including Arrangements With Affiliate$13.0M0.7%-73%
License and Royalty$11.0M0.6%-74%
RSV$8.00M0.4%-68%

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
MRNA Moderna, Inc. $90.4B +13% -116%No earnings35.8x No earnings

The company

Sector
Health Care
Industry
Biotechnology
CEO
Stéphane Bancel
Employees
5,800 (as of 2024)
Founded
2010
Headquarters
Cambridge, MA
Fiscal year ends
December
Website
modernatx.com

What it does

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about MRNA.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 491 active funds. Crowd level: crowd building, 3 rising quarters.

Open the Smart money tab